SHAREHOLDER ALERT: Weiss Law Investigates Forma Therapeutics Holdings, Inc.

NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Forma Therapeutics Holdings, Inc. ("Forma Therapeutics" or the "Company") (NASDAQ: FMTX), in connection with the proposed acquisition of the Company by Novo Nordisk A/S (NYSE: NVO) via tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $20.00 in cash for each share of Forma Therapeutics common stock owned.  The transaction is valued at approximately $1.1 billion.